<DOC>
	<DOCNO>NCT02523638</DOCNO>
	<brief_summary>Polycythemia Vera ( PV ) disease bone marrow stem cell manifest drastic increase red blood cell frequently also white blood cell . The `` thickening '' blood relation modify function cell several consequence like increase blood pressure , pruritus skin , fatigue , disturb blood circulation brain well finger toe increase risk arterial venous thrombosis ( thrombosis formation blood clot vessel ) ; like stroke , cardiac infarction , deep vein thrombosis leg . In case strong increase platelet additional risk bleeding . As disease progress size spleen liver increase case bone marrow show sign fibrosis . In case PV progression later time point leukemia ( increased formation white blood cell ) occur . The aim study assess ease AOP2014 self-administration use dedicated questionnaire . - To assess safety tolerability : adverse event ( AEs ) , laboratory parameter , electrocardiogram ( ECG ) throughout study . - To assess maintenance blood efficacy parameter Hct ( Hematocrit ) , WBC ( white blood cell ) PLTs ( platelet ) spleen size ( compare value Visit P7 vs. value Visit P1 ) . - To assess feasibility AOP2014 self-administration : defined ability patient use pen self-administration tool ( ease handling , safety , tolerability efficacy ) .</brief_summary>
	<brief_title>Study Assess Self-administration AOP2014 Using Pen , Developed Treatment Polycythemia Vera Patients</brief_title>
	<detailed_description>This Phase III , single-arm study perform patient complete AOP2014 arm PROUD-PV study currently participate CONTINUATION-PV study . After sign informed consent form ( ICF ) , approximately 30 patient enrol consecutively study participate site accord inclusion exclusion criterion .</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Patients either complete 12 month AOP2014 treatment arm PROUDPV study , currently participate CONTINUATIONPV , `` EoT visit '' ( End treatment visit ) PROUDPV study two week last assessment visit CONTINUATIONPV study , fulfill least one follow criterion : Normalization least two three main blood parameter ( Hct ( Hematocrit ) , PLTs ( Platelets ) WBCs ( white blood cell ) parameter moderately increase ( Hct &lt; 50 % , WBCs &lt; 20 x 109/L , PLTs &lt; 600 x 109/L ) baseline visit PROUDPV study , OR &gt; 35 % decrease least two three main blood parameter ( Hct , PLTs WBCs ) parameter massively increase ( Hct &gt; 50 % , WBCs &gt; 20 x 109/L , PLTs &gt; 600 x 109/L ) , baseline visit PROUDPV study , OR Normalization spleen size , spleen enlarge baseline visit PROUDPV study , OR Otherwise clear , medically verified benefit treatment AOP2014 ( e.g . normalization diseaserelated microvasculatory symptom , substantial decrease JAK2 ( Januskinase 2 ) allelic burden ) . 2 . Signed write ICF . Withdrawal criterion , specify PROUDPV CONTINUATIONPV study , mandate treatment discontinuation . 1 . Nonrecovery AOP2014 related toxicity grade ( usually , Grade I ) allow continuation treatment . 2 . HADS ( Hospital Anxiety Depression Scale ) score 11 high either subscales , /or development worsen clinically significant depression suicidal thought . 3 . Progressive clinically significant increase liver enzyme level despite dose reduction , increase accompany increased bilirubin level , sign symptom clinically significant autoimmune disease . 4 . Clinically significant development new ophthalmologic disorder , worsen preexist one , study . 5 . Loss efficacy AOP2014 comparable situation benefit treatment continuation expect investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Pegylated-Proline-interferon alpha-2b ( AOP2014 )</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>PEN-PV</keyword>
	<keyword>PROUD-PV</keyword>
	<keyword>CONTINUATION-PV</keyword>
	<keyword>AOP Orphan</keyword>
	<keyword>Polycythemia</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Interferon-alpha</keyword>
	<keyword>Peginterferon alfa-2b</keyword>
</DOC>